The Impact of AI Integration in Drug Development
AI’s revolutionary influence on pharmaceutical innovation is evident as it continues to permeate the industry.
AI’s revolutionary influence on pharmaceutical innovation is evident as it continues to permeate the industry.
Dr. Satz played a pivotal role in positioning actinium-225 as a promising radionuclide for targeted alpha therapy.
Driven by the dynamic duo of Dr. Stan and Ms. Rose Satz, AIP brings over four decades of nuclear pharmacy and radiochemistry expertise.
AIP ventures into uncharted territory of rare pediatric diseases.
AIP employs cutting-edge radiolabeling techniques to empower pharmaceutical breakthroughs.
The intricate landscape of drug-receptor interactions unfolds as a captivating tapestry of pharmacodynamic principles.
GPCRs are the unsung heroes of cellular communication, orchestrating a symphony of molecular events in response to a diverse array of signals
The need for efficient drug discovery tools is more critical than ever, prompting the development of a cheminformatics partitioning model that promises to unlock the drug-like potential of natural compounds.
EDED seeks to overcome the limitations of traditional ensemble docking techniques.
Alongside Tox21, the EPA’s ToxCast program is extending the frontier of toxicity prediction.
In the ever-evolving landscape of medicinal chemistry and cheminformatics, AI emerges as a formidable catalyst for innovation.
The acquisition of PrecisionMed by BioIVT marks a momentous occasion in the biospecimen industry.
Researchers investigated the therapeutic effects of ROCK inhibition in a mouse model with ARHGAP10 gene mutations, offering insights into the genetic basis of schizophrenia.
Lately, nanofluids have expanded their range of biological research applications, particularly as novel means of medication delivery.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings